Dermatological

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

But the French major is still keen on early-stage M&A.

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.

The Belgian firm has posted a healthy set of financials for 2024, buoyed by strong uptake in the US across all indications for Bimzelx.

CEO Christophe Bourdon tells Scrip that the Danish dermatology specialist is delivering consistently strong sales while maintaining financial discipline and has created the foundation for long-term growth.

The Spanish group has upped its peak sales guidance for Ilumetri to €300m and believes the arrival of Stelara biosimilars will take a while to have much of an impact on the originator IL-23 class.

Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.

Having built its portfolio from university collaborations and targeted in-licensing, the UK firm now hopes to validate its business model with Phase II readouts in 2025.

With Jakafi slated to lose US patent protection in 2028, Incyte is looking to GVHD launch product Niktimvo and label expansions for Opzelura, Monjuvi and Zynyz to drive late-decade growth.

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

The US biotech is paying $250m upfront to the Danish group in what is the second STAT6 deal secured in the past three weeks.